These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 26847076)

  • 21. Reduced long-term overall mortality in heart failure patients with prolonged QRS treated with CRT combined with ICD vs. heart failure patients with narrow QRS treated with ICD only.
    Palmisano P; Accogli M; Pisanò EC; Zaccaria M; De Blasi S; Ponzetta MA; Valsecchi S; Milanese G; Lauretti M; Magliari F
    Europace; 2016 Sep; 18(9):1374-82. PubMed ID: 26612878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ampere Hour as a Predictor of Cardiac Resynchronization Defibrillator Pulse Generator Battery Longevity: A Multicenter Study.
    Ellis CR; Dickerman DI; Orton JM; Hassan S; Good ED; Okabe T; Andriulli JA; Quan KJ; Greenspon AJ
    Pacing Clin Electrophysiol; 2016 Jul; 39(7):658-68. PubMed ID: 26875541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors and the effect of cardiac resynchronization therapy on cardiac and non-cardiac mortality in MADIT-CRT.
    Perkiomaki JS; Ruwald AC; Kutyifa V; Ruwald MH; Mcnitt S; Polonsky B; Goldstein RE; Haigney MC; Krone RJ; Zareba W; Moss AJ;
    Europace; 2015 Dec; 17(12):1816-22. PubMed ID: 26071234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complications in recipients of cardioverter-defibrillator or cardiac resynchronization therapy: Insights from Silesian Center Defibrillator registry.
    Tajstra M; Gadula-Gacek E; Kurek A; Adamowicz-Czoch E; Olszowski D; Ostręga M; Ciślak A; Pyka Ł; Hawranek M; Lekston A; Poloński L; Gąsior M
    Cardiol J; 2017; 24(5):515-522. PubMed ID: 27734455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Longevity of implantable cardioverter defibrillators: a comparison among manufacturers and over time.
    von Gunten S; Schaer BA; Yap SC; Szili-Torok T; Kühne M; Sticherling C; Osswald S; Theuns DA
    Europace; 2016 May; 18(5):710-7. PubMed ID: 26609076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PR interval identifies clinical response in patients with non-left bundle branch block: a Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy substudy.
    Kutyifa V; Stockburger M; Daubert JP; Holmqvist F; Olshansky B; Schuger C; Klein H; Goldenberg I; Brenyo A; McNitt S; Merkely B; Zareba W; Moss AJ
    Circ Arrhythm Electrophysiol; 2014 Aug; 7(4):645-51. PubMed ID: 24963007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rate, causes, and impact on patient outcome of implantable device complications requiring surgical revision: large population survey from two centres in Italy.
    Palmisano P; Accogli M; Zaccaria M; Luzzi G; Nacci F; Anaclerio M; Favale S
    Europace; 2013 Apr; 15(4):531-40. PubMed ID: 23407627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence and Costs Related to Lead Damage Occurring Within the First Year After a Cardiac Implantable Electronic Device Replacement Procedure.
    Nichols CI; Vose JG; Mittal S
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of functional Sprint Fidelis leads at cardiac resynchronization therapy-defibrillator generator replacement: a novel option for preventing inappropriate shocks from lead failure in fragile patients with high risk of sudden death.
    Zhu DWX; Chu MM; House CM
    Europace; 2017 Dec; 19(12):2007-2014. PubMed ID: 27940933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of cardiac resynchronization therapy and implantable cardioverter defibrillator on quality of life in patients with heart failure: a meta-analysis.
    Chen S; Yin Y; Krucoff MW
    Europace; 2012 Nov; 14(11):1602-7. PubMed ID: 23104857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implementation and reimbursement of remote monitoring for cardiac implantable electronic devices in Europe: a survey from the health economics committee of the European Heart Rhythm Association.
    Mairesse GH; Braunschweig F; Klersy K; Cowie MR; Leyva F
    Europace; 2015 May; 17(5):814-8. PubMed ID: 25713012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adding the implantable cardioverter-defibrillator to cardiac resynchronization therapy is associated with improved long-term survival in ischaemic, but not in non-ischaemic cardiomyopathy.
    Witt CT; Kronborg MB; Nohr EA; Mortensen PT; Gerdes C; Jensen HK; Nielsen JC
    Europace; 2016 Mar; 18(3):413-9. PubMed ID: 26378089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atrial fibrillation in cardiac resynchronization therapy with a defibrillator: a risk factor for mortality, appropriate and inappropriate shocks.
    van Boven N; Theuns D; Bogaard K; Ruiter J; Kimman G; Berman L; VAN DER Ploeg T; Kardys I; Umans V
    J Cardiovasc Electrophysiol; 2013 Oct; 24(10):1116-22. PubMed ID: 23889733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longevity of implantable cardioverter-defibrillators in a single-center population.
    Seegers J; Expósito PM; Lüthje L; Fischer T; Lueken M; Wenk H; Sossalla ST; Hasenfuss G; Zabel M
    J Interv Card Electrophysiol; 2015 Nov; 44(2):179-86. PubMed ID: 26253815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Importance of Implantable Cardioverter-Defibrillator Back-Up in Cardiac Resynchronization Therapy Recipients: A Systematic Review and Meta-Analysis.
    Barra S; Providência R; Tang A; Heck P; Virdee M; Agarwal S
    J Am Heart Assoc; 2015 Nov; 4(11):. PubMed ID: 26546574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimate and reporting of longevity for cardiac implantable electronic devices: a proposal for standardized criteria.
    Censi F; Calcagnini G; Mattei E; Ricci RP; Zoni Berisso M; Landolina M; Boriani G
    Expert Rev Med Devices; 2021 Dec; 18(12):1203-1208. PubMed ID: 34854774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Characteristics and Outcomes of Older Cardiac Resynchronization Therapy Recipients Using a Pacemaker versus a Defibrillator.
    Munir MB; Althouse AD; Rijal S; Shah MB; Abu Daya H; Adelstein E; Saba S
    J Cardiovasc Electrophysiol; 2016 Jun; 27(6):730-4. PubMed ID: 26856440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence of defibrillator shocks after elective generator exchange following uneventful first battery life.
    Merchant FM; Jones P; Wehrenberg S; Lloyd MS; Saxon LA
    J Am Heart Assoc; 2014 Nov; 3(6):e001289. PubMed ID: 25385346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Applicability of a risk score for prediction of the long-term benefit of the implantable cardioverter defibrillator in patients receiving cardiac resynchronization therapy.
    Barra S; Looi KL; Gajendragadkar PR; Khan FZ; Virdee M; Agarwal S
    Europace; 2016 Aug; 18(8):1187-93. PubMed ID: 26566940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relation of QRS Duration to Clinical Benefit of Cardiac Resynchronization Therapy in Mild Heart Failure Patients Without Left Bundle Branch Block: The Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy Substudy.
    Biton Y; Kutyifa V; Cygankiewicz I; Goldenberg I; Klein H; McNitt S; Polonsky B; Ruwald AC; Ruwald MH; Moss AJ; Zareba W
    Circ Heart Fail; 2016 Feb; 9(2):e002667. PubMed ID: 26823498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.